Evidence map›Paper›PMID 41342465›Full record

ArticleTransfusion2026

Suppression of RBC alloimmunization and regulation of CD4

Arijita Jash, Ariel Hay, James C Zimring

Abstract read
In one paragraph

Article in Transfusion, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Arijita JashBeirne Carter Immunology Center, University of Virginia, Charlottesville, Virginia, USA.
Ariel HayBeirne Carter Immunology Center, University of Virginia, Charlottesville, Virginia, USA.
James C ZimringBeirne Carter Immunology Center, University of Virginia, Charlottesville, Virginia, USA.ORCID https://orcid.org/0000-0002-6365-8825

Funding

Basic and Translational Mechanisms of Alloimmunization to RBC Transfusion Scientific Core AP01HL169552 · NHLBI · UNIVERSITY OF VIRGINIA · PI CHANCE MARION JOHN LUCKEY · 2023 to 2026
$11.3M
NHLBI NIH HHS P01 HL169552NIH HHS P01HL169552
6 · The paper itself

Abstract

backgroundActivation of complement protein C3 generally enhances antibody responses and C3-null mice have decreased antibody-based immunity. Mener et al. have reported a paradoxical suppressor function for C3 in alloimmunization to transfused RBCs as alloantibodies are increased in C3-null mice. Moreover, C3 regulated the CD4

methodsWe used CRISPR/Cas9 to generate a new C3-null mouse (C3Cr-KO) directly in B6 mice lacking any 129 genetic elements. B6 and C3Cr-KO mice were transfused with KEL-K2

resultsIdentical to the findings of Mener et al., alloimmunization was increased in C3Cr-KO mice compared to wild-type B6 mice and CD4

conclusionsThe current findings eliminate a common confounder present in murine knockout systems that has caused erroneous conclusions in other settings. Both the conclusion that the presence of the C3 gene decreases RBC alloimmunization and regulates CD4

Indexed as

CD4-Positive T-LymphocytesComplement C3ErythrocytesErythrocyte TransfusionIsoantibodiesAnimalsMiceMice, Inbred C57BLMice, KnockoutComplement C3Isoantibodies

Identifiers

PMID41342465
PMCPMC12857883

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.